118 related articles for article (PubMed ID: 26169968)
1. Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma.
Tierny D; Serres F; Segaoula Z; Bemelmans I; Bouchaert E; Pétain A; Brel V; Couffin S; Marchal T; Nguyen L; Thuru X; Ferré P; Guilbaud N; Gomes B
Clin Cancer Res; 2015 Dec; 21(23):5314-23. PubMed ID: 26169968
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II.
Brel V; Annereau JP; Vispé S; Kruczynski A; Bailly C; Guilbaud N
Biochem Pharmacol; 2011 Dec; 82(12):1843-52. PubMed ID: 21924246
[TBL] [Abstract][Full Text] [Related]
3. Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II.
Ballot C; Jendoubi M; Kluza J; Jonneaux A; Laine W; Formstecher P; Bailly C; Marchetti P
Apoptosis; 2012 Apr; 17(4):364-76. PubMed ID: 22127645
[TBL] [Abstract][Full Text] [Related]
4. F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer.
Thibault B; Clement E; Zorza G; Meignan S; Delord JP; Couderc B; Bailly C; Narducci F; Vandenberghe I; Kruczynski A; Guilbaud N; Ferré P; Annereau JP
Cancer Lett; 2016 Jan; 370(1):10-8. PubMed ID: 26404751
[TBL] [Abstract][Full Text] [Related]
5. F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.
Barret JM; Kruczynski A; Vispé S; Annereau JP; Brel V; Guminski Y; Delcros JG; Lansiaux A; Guilbaud N; Imbert T; Bailly C
Cancer Res; 2008 Dec; 68(23):9845-53. PubMed ID: 19047165
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, compared with etoposide phosphate, in dogs with naturally occurring lymphoma.
Boyé P; Floch F; Serres F; Segaoula Z; Hordeaux J; Pascal Q; Coste V; Courapied S; Bouchaert E; Rybicka A; Mazuy C; Marescaux L; Geeraert K; Fournel-Fleury C; Duhamel A; Machuron F; Ferré P; Pétain A; Guilbaud N; Tierny D; Gomes B
Oncotarget; 2020 Feb; 11(7):671-686. PubMed ID: 32133044
[No Abstract] [Full Text] [Related]
7. An integrated Drosophila model system reveals unique properties for F14512, a novel polyamine-containing anticancer drug that targets topoisomerase II.
Chelouah S; Monod-Wissler C; Bailly C; Barret JM; Guilbaud N; Vispé S; Käs E
PLoS One; 2011; 6(8):e23597. PubMed ID: 21853156
[TBL] [Abstract][Full Text] [Related]
8. Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines.
Leblond P; Boulet E; Bal-Mahieu C; Pillon A; Kruczynski A; Guilbaud N; Bailly C; Sarrazin T; Lartigau E; Lansiaux A; Meignan S
Invest New Drugs; 2014 Oct; 32(5):883-92. PubMed ID: 25008900
[TBL] [Abstract][Full Text] [Related]
9. The antitumor drug F14512 enhances cisplatin and ionizing radiation effects in head and neck squamous carcinoma cell lines.
Mouawad F; Gros A; Rysman B; Bal-Mahieu C; Bertheau C; Horn S; Sarrazin T; Lartigau E; Chevalier D; Bailly C; Lansiaux A; Meignan S
Oral Oncol; 2014 Feb; 50(2):113-9. PubMed ID: 24290982
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer.
Leary A; Le Tourneau C; Varga A; Sablin MP; Gomez-Roca C; Guilbaud N; Petain A; Pavlyuk M; Delord JP
Invest New Drugs; 2019 Aug; 37(4):693-701. PubMed ID: 30547316
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation study to evaluate safety, tolerability and efficacy of intravenous etoposide phosphate administration in 27 dogs with multicentric lymphoma.
Boyé P; Serres F; Marescaux L; Hordeaux J; Bouchaert E; Gomes B; Tierny D
PLoS One; 2017; 12(5):e0177486. PubMed ID: 28505195
[TBL] [Abstract][Full Text] [Related]
12. Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage.
Gentry AC; Pitts SL; Jablonsky MJ; Bailly C; Graves DE; Osheroff N
Biochemistry; 2011 Apr; 50(15):3240-9. PubMed ID: 21413765
[TBL] [Abstract][Full Text] [Related]
13. Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system.
Kruczynski A; Vandenberghe I; Pillon A; Pesnel S; Goetsch L; Barret JM; Guminski Y; Le Pape A; Imbert T; Bailly C; Guilbaud N
Invest New Drugs; 2011 Feb; 29(1):9-21. PubMed ID: 19777159
[TBL] [Abstract][Full Text] [Related]
14. F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.
Kruczynski A; Pillon A; Créancier L; Vandenberghe I; Gomes B; Brel V; Fournier E; Annereau JP; Currie E; Guminski Y; Bonnet D; Bailly C; Guilbaud N
Leukemia; 2013 Nov; 27(11):2139-48. PubMed ID: 23568148
[TBL] [Abstract][Full Text] [Related]
15. An optimized polyamine moiety boosts the potency of human type II topoisomerase poisons as quantified by comparative analysis centered on the clinical candidate F14512.
Palermo G; Minniti E; Greco ML; Riccardi L; Simoni E; Convertino M; Marchetti C; Rosini M; Sissi C; Minarini A; De Vivo M
Chem Commun (Camb); 2015 Oct; 51(76):14310-3. PubMed ID: 26234198
[TBL] [Abstract][Full Text] [Related]
16. The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks.
Bombarde O; Larminat F; Gomez D; Frit P; Racca C; Gomes B; Guilbaud N; Calsou P
Mol Cancer Ther; 2017 Oct; 16(10):2166-2177. PubMed ID: 28611105
[TBL] [Abstract][Full Text] [Related]
17. A fluorescent biomarker of the polyamine transport system to select patients with AML for F14512 treatment.
Annereau JP; Brel V; Dumontet C; Guminski Y; Imbert T; Broussas M; Vispé S; Bréand S; Guilbaud N; Barret JM; Bailly C
Leuk Res; 2010 Oct; 34(10):1383-9. PubMed ID: 20096930
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors.
Selting KA; Wang X; Gustafson DL; Henry CJ; Villamil JA; McCaw DL; Tate D; Beittenmiller M; Garnett C; Robertson JD
J Vet Intern Med; 2011; 25(4):909-15. PubMed ID: 21564292
[TBL] [Abstract][Full Text] [Related]
19. Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma.
Paoloni M; Mazcko C; Selting K; Lana S; Barber L; Phillips J; Skorupski K; Vail D; Wilson H; Biller B; Avery A; Kiupel M; LeBlanc A; Bernhardt A; Brunkhorst B; Tighe R; Khanna C
PLoS One; 2015; 10(6):e0129954. PubMed ID: 26091536
[TBL] [Abstract][Full Text] [Related]
20. Phase I study to determine the maximal tolerated dose and dose-limiting toxicities of orally administered idarubicin in dogs with lymphoma.
Vail DM; Husbands BD; Kamerling SG; Simpson H; Kurzman ID; McDonnell A
J Vet Intern Med; 2012; 26(3):608-13. PubMed ID: 22404399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
